Impact of Residual SYNTAX Score and Its Derived Indexes on Clinical Outcomes after Percutaneous Coronary Intervention: Data from a Large Single Center

Ying Song, Zhan Gao, Xiao-Fang Tang, Ping Jiang, Jing-Jing Xu, Yi Yao, Jian-Xin Li, Xue-Yan Zhao, Shu-Bin Qiao, Yue-Jin Yang, Run-Lin Gao, Bo Xu, Jin-Qing Yuan

Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing100037, China

Abstract

Background: Residual SYNTAX score (rSS) and its derived indexes including SYNTAX revascularization index (SRI) and clinical rSS had been developed to quantify and describe the extent of incomplete revascularization. This study was conducted to explore the utility of the three scores among real-world patients after percutaneous coronary intervention (PCI).

Methods: From January 2013 to December 2013, patients underwent PCI treatment at Fuwai Hospital were included. The primary endpoints were all-cause death and major adverse cardiovascular and cerebrovascular events. The secondary endpoints were myocardial infarction, revascularization, stroke, and stent thrombosis. Kaplan-Meier methodology was used to determine the outcomes. Cox multivariable regression was to test the associations between scores and all-cause mortality.

Results: A total of 10,344 patients were finally analyzed in this study. Kaplan-Meier survival analysis indicated that greater residual coronary lesions quantified by rSS and its derived indexes were associated with increased risk of adverse cardiovascular events. However, after multivariate analysis, only clinical rSS was an independent predictor of 2-year all-cause death (hazard ratio: 1.02, 95% confidence interval: 1.01–1.03, P < 0.01). By receiver operating characteristic (ROC) curve analysis, clinical rSS had superior predictability of 2-year all-cause death than rSS and SRI (area under ROC curve [AUC]: 0.59 vs. 0.56 vs. 0.56, all P < 0.01), whereas rSS was superior in predicting repeat revascularization than clinical rSS and SRI (AUC: 0.62 vs. 0.61 vs. 0.61; all P < 0.01). When comparing the predictive capability of rSS ≥8 with SRI <70%, their predictabilities were not significantly different.

Conclusions: This study indicates that all three indexes (rSS, clinical rSS, and SRI) are able to risk-stratify patients and predict 2-year outcomes after PCI. However, their prognostic capabilities are different.

Key words: Clinical Outcome; Percutaneous Coronary Intervention; Risk Assessment; Risk Stratification

Introduction

For patients with multivessel coronary disease, percutaneous coronary intervention (PCI) frequently involves incomplete revascularization (IR) because of coronary anatomy complexity or coexisting serious clinical conditions. The prognostic impact of IR after PCI had been inconsistent among studies, and one potential explanation was due to the lack of consent definition of IR. Among them, rSS and SRI were purely anatomic indexes: rSS represented untreated baseline lesions in coronary artery, and SRI represented the proportion of lesions requiring revascularization given a certain therapeutic strategy. Recently, residual SYNTAX score (rSS) and its derived other two indexes including SYNTAX revascularization index (SRI) and clinical rSS had been developed as the tool to better quantify and describe the extent of IR. Among them, rSS and SRI were purely anatomic indexes: rSS represented untreated baseline lesions in coronary artery, and SRI represented the proportion...
of treated baseline coronary artery lesion.\(^{[14,15]}\) Whereas, clinical rSS was an index combining anatomic (rSS) with clinical variables (modified age, creatinine, and ejection fraction [ACEF] score).\(^{[16]}\)

Although the indexes aforementioned had been proven to have prognostic capacity after PCI,\(^{[8‑16]}\) to date, few studies have explored the utility of all these indexes among the unselective real-world patients undergoing contemporary PCI treatment. Therefore, the present study was conducted to assess and compare the prognostic capacity of these indexes in a large cohort population of patients undergoing PCI in daily practice.

### METHODS

#### Ethical approval

The study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of Fuwai Hospital (Approval No. 2013‑449), and each patient provided informed written consent written informed consent before PCI.

#### Study population

This study was a cohort study and 10,723 consecutive patients who underwent PCI treatment at Fuwai Hospital, National Center for Cardiovascular Diseases, from January to December 2013, were included. After excluding patients with a history of previous coronary artery bypass grafting, 10,344 patients were finally analyzed in this study. The SYNTAX score (SS) and the rSS from all coronary angiograms, using standard quantitative coronary analysis methodology, were assessed by an independent angiographic core laboratory blinded to clinical outcomes.\(^{[9,17]}\) The SRI was calculated with the following formula: SRI = (1‑rSS/baseline SS) × 100.\(^{[14]}\) The clinical rSS was calculated by multiplying the rSS with the “modified ACEF” score.\(^{[18]}\)

#### Procedures and medications

The PCI strategies and stent types were left to treating physician’s discretion. If not taking long-term aspirin and P2Y12 inhibitors, selective PCI patients received oral 300 mg aspirin and clopidogrel (loading dose 300 mg) or ticagrelor (loading dose 180 mg) at least 24 h before the procedure. Patients with acute coronary syndrome scheduled for primary PCI received the same dose aspirin and ticagrelor or clopidogrel (loading dose 300 mg or 600 mg) as soon as possible. During the procedure, unfractionated heparin (100 U/kg) was administered to all patients, and use of glycoprotein IIb/IIIa inhibitors was depended on operator’s judgment. After the procedure, aspirin was prescribed at a dose of 100 mg daily indefinitely; clopidogrel 75 mg daily or ticagrelor 90 mg twice daily was advised for at least 1 year after PCI.

#### Patient follow-up

All patients were evaluated by clinic visit or by phone at 1, 3, 6, and 12 months and annually thereafter. Patients were advised to return for coronary angiography if clinically indicated by symptoms or documentation of myocardial ischemia. Two-year follow-up was completed for 10,287 (99.4%) patients.

### Endpoints and definitions

Myocardial infarction (MI) was defined by the third universal definition of MI.\(^{[19]}\) Revascularization was defined as repeated revascularization for ischemic symptoms and events driven by PCI or surgery of any vessel. Stent thrombosis (ST) was defined on the basis of the Academic Research Consortium definitions according to the level of certainty as definite, probable, and possible.\(^{[20]}\) Major adverse cardiovascular and cerebrovascular events (MACCEs) were defined as the occurrence of death, MI, revascularization, ST, and stroke during follow-up period. Procedural success was defined as residual stenosis 50% and without in-hospital MACCE. All endpoints were adjudicated centrally by two independent cardiologists, and disagreement was resolved by consensus.

### Statistical analysis

Continuous variables are shown as mean ± standard deviation (SD) or median (Q1, Q3), while categorical variables are reported as counts or percentage. For the baseline characteristics, generalized linear models were used to compare continuous variables across rSS groups with rSS class as a covariable, while the Cochran-Armitage test for trends was used for categorical data. Clinical outcomes were determined using Kaplan-Meier methodology. To test for possible associations between the SYNTAX indexes and the rates of long-term mortality, stepwise Cox multivariable regression analysis was used, with variable entry/stay criteria of 0.1/0.1. In addition, variables historically known to be associated with long-term mortality were included in the model. The proportional hazard assumption was verified for each endpoint using the supremum test. Receiver operating characteristic curves were used to compare the prognostic ability of the various risk scores to predict the rates of ischemic adverse events. Statistical analyses were performed using SPSS version 23 (IBM Corporation, Armonk, New York, USA). A \( P < 0.05 \) was considered statistically significant.

### Results

#### Patients and baseline characteristics

The mean baseline SS was 13.6 ± 9.1 (range: 1.0–58.0), and the complete revascularization (CR) (rSS = 0, clinical rSS = 0, and SRI = 100) was achieved in 52.0% (5375/10,344) of patients. Patients who underwent IR were further categorized into three groups according to rSS, clinical rSS, and SRI tertiles [Table 1 and Supplementary Tables 1, 2]. Patients in higher rSS levels had higher clinical risks including older age, decreased renal function, lower LVEF, more comorbidities, and higher baseline SS. Similarly, patients in higher clinical rSS and lower SRI levels had similar baseline characteristics as in higher rSS levels.
Table 1: Baseline characteristics of all patients after PCI according to rSS

| Characteristics          | rSS = 0 (n = 5375) | 0< rSS ≤S4 (n = 1995) | 4< rSS ≤S8 (n = 1408) | rSS >S8 (n = 1686) | Statistical values | P (for trend) |
|--------------------------|--------------------|------------------------|-----------------------|-------------------|-------------------|--------------|
| Age (years)              | 57 ± 10            | 58 ± 10                | 59 ± 10               | 60 ± 10           | 39.21†           | < 0.01       |
| Male                     | 4140 (77.0)        | 1523 (76.3)            | 1095 (77.9)           | 1210 (77.2)       | 1.13†            | 0.77         |
| BMI (kg/m²)              | 25.9 ± 3.2         | 26.0 ± 3.2             | 26.0 ± 3.1            | 26.0 ± 3.1        | 0.78*            | 0.51         |
| eGFR <90 ml/min          | 1871 (34.8)        | 767 (38.4)             | 599 (42.6)            | 708 (45.2)        | 70.19†           | < 0.01       |
| LVEF <40 ml/min          | 17 (0.3)           | 6 (0.3)                | 7 (0.5)               | 9 (0.6)           | 6.02†            | 0.11         |
| **Clinical history**     |                    |                        |                       |                   |                   |              |
| Diabetes mellitus        | 1398 (26.0)        | 709 (35.5)             | 447 (31.8)            | 554 (35.3)        | 93.18†           | < 0.01       |
| Hypertension             | 3321 (61.8)        | 1350 (67.7)            | 909 (64.7)            | 1061 (67.7)       | 32.39†           | < 0.01       |
| Hyperlipidemia           | 3545 (66.0)        | 1380 (69.2)            | 966 (68.7)            | 1051 (67.0)       | 8.73†            | 0.03         |
| Previous stroke          | 491 (9.1)          | 242 (12.1)             | 162 (11.5)            | 214 (13.6)        | 33.24†           | < 0.01       |
| Peripheral vascular disease | 121 (2.3)       | 53 (2.7)               | 39 (2.8)              | 57 (3.6)          | 9.37†            | 0.02         |
| COPD                     | 114 (2.1)          | 44 (2.2)               | 39 (2.8)              | 39 (2.5)          | 2.50†            | 0.48         |
| Family history of CAD    | 1298 (24.2)        | 510 (25.6)             | 330 (23.5)            | 414 (26.4)        | 5.26†            | 0.15         |
| Current smoker           | 3057 (56.9)        | 1143 (57.3)            | 797 (56.7)            | 891 (56.8)        | 0.16†            | 0.98         |
| Previous MI              | 884 (16.4)         | 373 (18.7)             | 298 (21.2)            | 366 (23.3)        | 46.06†           | < 0.01       |
| Previous PCI             | 1203 (22.4)        | 503 (25.2)             | 386 (27.5)            | 424 (27.0)        | 25.64†           | < 0.01       |
| **Clinical presentation**|                    |                        |                       |                   |                   |              |
| ACS                      | 3334 (62.0)        | 1180 (59.1)            | 832 (59.2)            | 891 (56.8)        | 15.27†           | < 0.01       |
| Stable angina            | 1620 (30.1)        | 647 (32.4)             | 463 (32.9)            | 529 (33.7)        |                   |              |
| Silent ischemia          | 421 (7.8)          | 168 (8.4)              | 111 (7.9)             | 148 (9.4)         |                   |              |

The data are shown as mean ± SD or n (%). *F value; †Chi-square value. BMI: Body mass index; eGFR: Estimated glomerular filtration rate; LVEF: Left ventricular ejection fraction; COPD: Chronic obstructive pulmonary disease; CAD: Coronary artery disease; MI: Myocardial infarction; PCI: Percutaneous coronary intervention; ACS: Acute coronary syndrome; BMS: Bare metal stent; DES: Drug-eluting stent; PTCA: Percutaneous transluminal coronary angioplasty; IVUS: Intravenous ultrasound; IABP: Intra-aortic balloon pump; rSS: Residual SYNTAX score; SD: Standard deviation; LM: Left main.

**Clinical outcomes**

As shown in Figure 1, among different rSS groups, there were significant differences of the rates of all-cause death (1.0% vs. 1.1% vs. 1.4% vs. 1.8%, P < 0.01), revascularization (5.8% vs. 9.7% vs. 10.0% vs. 15.4%, P < 0.01), and MACCE (8.7% vs. 13.4% vs. 20.0%, P < 0.01). Moreover, there were also significant differences of the rates of all-cause death (1.0% vs. 0.9% vs. 0.7% vs. 2.5%, P < 0.01), revascularization (5.8% vs. 9.7% vs. 10.5% vs. 14.6%, P < 0.01), and MACCE (8.7% vs. 13.0% vs. 13.8% vs. 20.0%, P < 0.01) among different clinical rSS groups [Figure 1]. Patients in higher rSS or clinical rSS groups had higher incidence of adverse clinical events. Although the incidence of all-cause death was not different among patients in different SRI groups (1.0% vs. 1.1% vs. 2.6% vs. 2.5%, P = 0.13), rates of revascularization (5.8% vs. 10.7% vs. 9.7% vs. 14.4%, P < 0.01) and MACCE (8.7% vs. 14.3% vs. 13.7% vs. 18.8%, P < 0.01) were still significantly higher in patients in lower SRI groups [Figure 1]. After multivariate analysis, only clinical rSS was an independent predictor of 2-year mortality (hazard ratio: 1.02, 95% confidence interval: 1.01–1.03; P < 0.01); however, all these three indexes were independent predictors of MI, revascularization, and MACCE [Figure 2].

**Predictive capability of residual SYNTAX score, clinical residual SYNTAX score, and SYNTAX revascularization index**

By receiver operating characteristic (ROC) curve analysis, all these IR indexes were significantly associated with adverse cardiac events [Table 2]. When comparing these IR indexes with each other, the clinical rSS had superior predictability of 2-year all-cause death than rSS (area under ROC curve [AUC]: 0.59 vs. 0.56, P < 0.01) and SRI (AUC: 0.59 vs. 0.56, P < 0.01), and the rSS was
superior in predicting repeat revascularization than clinical rSS (AUC: 0.62 vs. 0.61, P < 0.01) and SRI (AUC: 0.62 vs. 0.61, P < 0.01). Of note, when only comparing the predictive capability of rSS ≥8 with SRI <70%, their predictabilities of 2-year all-cause death (AUC: 0.54, 95% confidence interval [CI]: 0.53–0.55 vs. AUC: 0.57, 95% CI: 0.56–0.58, P = 0.21), repeat revascularization (AUC: 0.57, 95% CI: 0.56–0.58 vs. AUC: 0.57, 95% CI: 0.56–0.58, P = 0.47), and MACCE (AUC: 0.56, 95% CI: 0.55–0.57 vs. AUC: 0.57, 95% CI: 0.59–0.58, P = 0.09) were not significant different.

**Discussion**

In this study, which included a large cohort of real-world patients undergoing contemporary PCI treatment, we assessed the degree of IR by rSS and its derived indexes (clinical rSS and SRI) on clinical outcomes. The major findings of this study were as follows: (1) all these IR indexes were able to risk-stratify patients and predict 2-year composite adverse cardiovascular and cerebrovascular events.

**Figure 1:** Kaplan-Meier curve showing event rates stratified by rSS (a), CrSS (b), and SRI (c) scores through 2 years. rSS: Residual SYNTAX score; CrSS: Clinical residual SYNTAX score; SRI: SYNTAX revascularization index; MACCE: Major adverse cardiovascular and cerebrovascular events.
This study assessed the prognostic capacity of all these IR indexes in one same large cohort, which added evidence of using rSS and its derived scores to evaluate and guide the revascularization of PCI treatment. The results demonstrated that all these IR indexes were able to risk-stratify patients and predict 2-year composite adverse cardiovascular events after PCI. Clinicians could select either of these indexes as a tool to quantify and describe the extent of IR by PCI revascularization and to predict patients' prognosis. In addition, we also found in the present study that only clinical rSS was an independent predictor of 2-year mortality after multivariate analysis. It was because that one of the outstanding limitations of rSS and SRI were lesion-based scoring system only including angiographic variables. Prior reports have demonstrated that combining the modified ACEF score with the SS could improve the ability of SS values to predict clinical outcomes. And just as a recently published report indicated, the clinical rSS, which combined the modified ACEF score with the rSS, significantly improved the predictability of rSS for all-cause death. In the present study, we also found that the clinical rSS had best predictability of all-cause death. Because clinical rSS incorporated clinical factors with scoring system, this difference of predictability seemed logical. On the other hand, this study found that rSS had better predictability of repeat revascularization than clinical rSS; this finding revealed a clinical phenomenon that when interventionists gave a patient a repeat revascularization, anatomic rSS was the index they focused on. However, both as anatomic IR indexes, the reason why rSS and SRI expressed significantly difference in predicting repeat revascularization was unclear.
However, when comparing the two IR cutoff values of rSS and SRI (rSS ≥ 8 vs. SRI < 70%) directly, we found that their predictabilities of 2-year all-cause death, repeat revascularization, and MACCE were not different.

The present study has some limitations that should be acknowledged. First, the major limitation of this study is its nonrandomized design in which unmeasured confounders might affect any definitive conclusion. Second, 2-year follow-up duration is comparatively short to evaluate long-term outcomes. Third, rSS is based on angiographic interpretation that has inherent limitations,[23] and the results might have varied if the SS was assessed by less-trained readers. However, rSS was assessed by an independent angiographic core laboratory in this study; the good reproducibility for baseline SS evaluation has been demonstrated.[24] Third, previous studies have shown that patients with functional IR showed significantly higher rate of MACCE than those with functional CR.[25] In this study, we did not have data to discuss the effect of functional rSS on long-term outcomes. Finally, the patients in this study only included those underwent PCI treatment, and these IR indexes should be also validated in patients received coronary artery bypass grafting therapy.

In conclusion, in this large cohort of real-world patients underwent PCI treatment, all these IR indexes (rSS, clinical rSS, and SRI) were able to risk-stratify patients and predict 2-year composite adverse cardiovascular events after PCI. However, their prognostic capabilities were different. Clinical rSS is superior in predicting 2-year all-cause death than other two anatomic rSS and SRI, whereas rSS has superior predictability of repeat revascularization than clinical rSS and SRI.

Supplementary information is linked to the online version of the paper on the Chinese Medical Journal website.

Financial support and sponsorship
This study was supported by grants from National Key R&D Program of China (No. 2016YFC1301300 and No. 2016YFC1301301), and National Natural Science Foundation of China (No. 81770365).

Conflicts of interest
There are no conflicts of interest.

Table 2: ROC: Predictive performance of outcomes with rSS, CrSS, and SRI

| Items               | rSS   | CrSS  | SRI   |
|---------------------|-------|-------|-------|
|                     | AUC (95% CI) | P     | AUC (95% CI) | P     | AUC (95% CI) | P     |
| All-cause death     | 0.56 (0.56–0.57) | 0.03  | 0.59 (0.58–0.60) | 0.03  | 0.56 (0.55–0.57) | 0.03  |
| Cardiac death       | 0.60 (0.59–0.61) | 0.04  | 0.63 (0.62–0.64) | 0.04  | 0.59 (0.58–0.60) | 0.04  |
| MI                  | 0.55 (0.54–0.56) | 0.03  | 0.56 (0.55–0.57) | <0.01 | 0.55 (0.54–0.56) | 0.02  |
| Revascularization   | 0.62 (0.61–0.62) | 0.01  | 0.61 (0.60–0.62) | 0.01  | 0.61 (0.60–0.62) | 0.01  |
| MACCE               | 0.60 (0.59–0.61) | 0.01  | 0.60 (0.59–0.61) | 0.01  | 0.60 (0.58–0.60) | 0.01  |

rSS: Residual SYNTAX score; CrSS: Clinical residual SYNTAX score; SRI: SYNTAX revascularization index; MACCE: Major adverse cardiovascular and cerebrovascular events; AUC: Area under ROC curve; CI: Confidence interval; ROC: Receiver operating characteristic; MI: Myocardial infarction.

References
1. McLellan CS, Ghali WA, Labinaz M, Davis RB, Galbraith PD, Southern DA, et al. Association between completeness of percutaneous coronary revascularization and postprocedure outcomes. Am Heart J 2005;150:800-6. doi: 10.1016/j.ahj.2004.10.037.
2. Bourassa MG, Yeh W, Holubkov R, Sopko G, Detre KM. Long-term outcome of patients with incomplete vs. complete revascularization after multivessel PTCA. A report from the NHLBI PTCA registry. Eur Heart J 1998;19:103-11.
3. He JQ, Yu XP, Peng C, Li Q, Luo YW, Gao YC, et al. Predictive ability of the SYNERgy between percutaneous coronary intervention with TAXus and cardiac surgery score II for long-term mortality in patients with three-vessel coronary artery disease undergoing percutaneous coronary intervention treated with second-generation drug-eluting stents. Chin Med J 2015;128:2176-82. doi: 10.4103/0366-6999.162510.
4. Rosner GF, Kirtane AJ, Genereux P, Lansky AJ, Cristea E, Gersh BJ, et al. Impact of the presence and extent of incomplete angiographic revascularization after percutaneous coronary intervention in acute coronary syndromes: The Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. Circulation 2012;125:2613-20. doi: 10.1161/CIRCULATIONAHA.111.069237.
5. Hannan EL, Wu C, Walford G, Holmes DR, Jones RH, Sharma S, et al. Incomplete revascularization in the era of drug-eluting stents: Impact on adverse outcomes. JACC Cardiovasc Interv 2009;2:17-25. doi: 10.1016/j.jcin.2008.08.021.
6. Kim YH, Park DW, Lee JY, Kim WJ, Yun SC, Ahn JM, et al. Impact of angiographic complete revascularization after drug-eluting stent implantation or coronary artery bypass graft surgery for multivessel coronary artery disease. Circulation 2011;123:2373-81. doi: 10.1161/CIRCULATIONAHA.110.055041.
7. Gao Z, Xu B, Yang YJ, Yuan JQ, Chen J, Chen JL, et al. Long-term outcomes of complete versus incomplete revascularization after drug-eluting stent implantation in patients with multivessel coronary disease. Catheter Cardiovasc Interv 2013;82:343-9. doi: 10.1002/ccd.24799.
8. Patel MR, Dehmer GJ, Hirshfeld JW, Smith PK, Spertus JA. ACCF/SCAI/STS/AATS/AHA/ASNC/HFA/SCCT 2012 appropriate use criteria for coronary revascularization focused update: A report of the American College of Cardiology Foundation Appropriateness Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, American Society of Nuclear Cardiology, and the Society of Cardiovascular Computed Tomography. J Am Coll Cardiol 2012;59:857-81. doi: 10.1016/j.jacc.2011.12.001.
9. Généreux P, Palmerini T, Caixeta A, Rosner G, Green P, Dressler O, et al. Quantification and impact of untreated coronary artery disease after percutaneous coronary intervention: The residual SYNTAX (Synergy between PCI with taxus and cardiac surgery) score. J Am Coll Cardiol 2012;59:2165-74. doi: 10.1016/j.jacc.2012.03.010.
10. Farooq V, Serruya PW, Bourantas CV, Zhang Y, Muramatsu T, Feldman T, et al. Quantification of incomplete revascularization and its association with five-year mortality in the synergy
between percutaneous coronary intervention with taxus and cardiac surgery (SYNTAX) trial validation of the residual SYNTAX score. Circulation 2013;128:141‑51. doi: 10.1161/CIRCULATIONAHA.113.001803.

11. Malkin CJ, George V, Ghobrial MS, Krishnan A, Siotia A, Raina T, et al. Residual SYNTAX score after PCI for triple vessel coronary artery disease: Quantifying the adverse effect of incomplete revascularisation. EuroIntervention 2013;8:1286‑95. doi: 10.4244/EIJV8I11A197.

12. Capodanno D, Chisari A, Giacoppo D, Bonura S, Lavanco V, Capranzano P, et al. Objectifying the impact of incomplete revascularization by repeat angiographic risk assessment with the residual SYNTAX score after left main coronary artery percutaneous coronary intervention. Catheter Cardiovasc Interv 2013;82:333‑40. doi: 10.1002/ccd.24642.

13. Xu B, Yang YJ, Han YL, Lu SZ, Li B, Liu Q, et al. Validation of residual SYNTAX score with second-generation drug‑eluting stents: One‑year results from the prospective multicentre SEEDS study. EuroIntervention 2014;10:65‑73. doi: 10.4244/EIJV10I1A12.

14. Généreux P, Campos CM, Yadav M, Palmerini T, Caixeta A, Xu K, et al. Reasonable incomplete revascularisation after percutaneous coronary intervention: The SYNTAX revascularisation index. EuroIntervention 2015;11:634‑42. doi: 10.4244/EIJY14M10_05.

15. Généreux P, Campos CM, Farooq V, Bourantas CV, Mohr FW, Colombo A, et al. Validation of the SYNTAX revascularization index to quantify reasonable level of incomplete revascularization after percutaneous coronary intervention. Am J Cardiol 2015;116:174‑86. doi: 10.1016/j.amjcard.2015.03.056.

16. Park KW, Kang J, Kang SH, Ahn HS, Kang HJ, Koo BK, et al. The impact of residual coronary lesions on clinical outcomes after percutaneous coronary intervention: Residual SYNTAX score after percutaneous coronary intervention in patients from the efficacy of xience/promus versus cypher in reducing late loss after stenting (EXCELLENT) registry. Am Heart J 2014;167:384‑92. doi: 10.1016/j.ahj.2013.09.015.

17. Sianos G, Morel MA, Kappelein AP, Morice MC, Colombo A, Dawkins K, et al. The SYNTAX score: An angiographic tool grading the complexity of coronary artery disease. EuroIntervention 2005;1:219‑27.

18. Garg S, Sarno G, Garcia-Garcia HM, Girasis C, Wykrzykowsa J, Dawkins KD, et al. A new tool for the risk stratification of patients with complex coronary artery disease: The clinical SYNTAX score. Circ Cardiovasc Interv 2010;3:317‑26. doi: 10.1161/CIRCINTERVENTIONS.109.914051.

19. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. Eur Heart J 2012;33:2551‑67. doi: 10.1016/j.ejcc.2012.08.001.

20. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007;115:2344‑51. doi: 10.1161/CIRCULATIONAHA.106.685313.

21. Li Y, Dong R, Huak K, Liu TS, Zhu SY, Zhou N, et al. Outcomes of coronary artery bypass grafting surgery versus percutaneous coronary intervention in patients aged 18‑45 years with diabetes mellitus. Chin Med J 2017;130:2906‑15. doi: 10.4103/0366‑6999.220305.

22. Girasis C, Garg S, Räber L, Sarno G, Morel MA, Garcia-Garcia HM, et al. SYNTAX score and clinical SYNTAX score as predictors of very long-term clinical outcomes in patients undergoing percutaneous coronary interventions: A substudy of sirolimus-eluting stent compared with paclitaxel-eluting stent for coronary revascularization (SIRTAX) trial. Eur Heart J 2011;32:3115‑27. doi: 10.1093/eurheartj/ehr369.

23. Tonino PA, Fearon WF, De Bruyne B, Oldroyd KG, Leesar MA, Ver Lee PN, et al. Angiographic versus functional severity of coronary artery stenoses in the FAME study fractional flow reserve versus angiography in multivessel evaluation. J Am Coll Cardiol 2010;55:2816‑21. doi: 10.1016/j.jacc.2009.11.096.

24. Choi KH, Lee JM, Koo BK, Nam CW, Shin ES, Doh JH, et al. Prognostic implication of functional incomplete revascularization and residual functional SYNTAX score in patients with coronary artery disease. JACC Cardiovasc Interv 2018;11:237‑45. doi: 10.1016/j.jcin.2017.09.009.
残余SYNTAX积分及其衍生积分对冠状动脉介入治疗术后患者预后影响的单中心大样本研究

摘要

背景：残余SYNTAX积分（rSS）及其衍生的SYNTAX血运重建指数（SRI）和临床残余SYNTAX积分（CrSS）被用于评价不完全血运重建的程度。本研究在真实世界行冠状动脉介入治疗的大样本人群中，研究rSS、SRI及CrSS对不完全血运重建的评价价值以及其对患者远期预后的预测价值。

研究方法：本研究连续纳入2013年1月至2013年12月在中国医学科学院阜外医院行冠状动脉介入治疗的患者。主要研究终点为全因死亡和主要心脑血管不良事件（MACCE），次要终点为再发心肌梗死、血运重建、卒中和支架内血栓。采用Kaplan-Meier法对临床终点进行生存分析，采用多因素COX回归分析比较三种积分与全因死亡的关系。使用受试者工作曲线比较三种不同积分对缺血事件的预测价值。

结果：研究共纳入10,344例患者。Kaplan-Meier生存分析显示：rSS、SRI及CrSS评价的残余冠状动脉病变更重的患者，其缺血事件发生率更高。多因素分析显示：CrSS是全因死亡的独立危险因素（HR: 1.02, 95% CI: 1.01–1.03; P<0.01）。受试者工作曲线比较分析显示：CrSS比rSS和SRI对全因死亡的预测价值更高（AUC: 0.59 vs. 0.56 vs. 0.56, P<0.01），而rSS比CrSS和SRI对再次血运重建的预测价值更高（AUC: 0.62 vs. 0.61 vs. 0.61, P<0.01）。rSS ≥ 8分和SRI< 70%对全因死亡的预测价值相当（AUC: 0.54, 95% CI: 0.53–0.55 vs. AUC: 0.57, 95% CI: 0.56–0.58, P=0.21）。

结论：rSS、CrSS和SRI三个评分均可用于冠状动脉介入治疗术后患者2年预后的危险分层。CrSS对全因死亡有一定的预测价值，rSS对再次血运重建有一定的预测价值。
# Supplementary Table 1: Baseline characteristics of all patients after PCI according to CrSS

| Characteristics                             | CrSS = 0 (n = 5375) | 0< CrSS ≤3.5 (n = 1667) | 3.5< CrSS ≤7.9 (n = 1641) | CrSS >7.9 (n = 1661) | Statistical values | P for trend |
|---------------------------------------------|----------------------|--------------------------|---------------------------|----------------------|---------------------|-------------|
| Age (years)                                 | 57 ± 10              | 59 ± 10                  | 59 ± 10                   | 60 ± 10              | 141.01*             | <0.01       |
| Male                                        | 4140 (77.0)          | 1306 (78.3)              | 1290 (78.6)               | 1232 (74.2)          | 11.61†              | <0.01       |
| BMI (kg/m²)                                 | 25.9 ± 3.2           | 26.0 ± 3.2               | 25.9 ± 3.1                | 26.0 ± 3.1           | 1.76*               | 0.49        |
| eGFR <90 ml/min                             | 1871 (34.8)          | 542 (32.5)               | 637 (38.8)                | 895 (53.9)           | 222.74*             | <0.01       |
| LVEF <40 ml/min                             | 17 (0.3)             | 6 (0.3)                  | 7 (0.5)                   | 9 (0.6)              | 40.57†              | <0.01       |
| Clinical history                            |                      |                          |                           |                      |                     |             |
| Diabetes mellitus                           | 1398 (26.0)          | 582 (34.9)               | 538 (32.8)                | 590 (35.5)           | 89.99*              | <0.01       |
| Hypertension                                | 3321 (61.8)          | 1110 (66.6)              | 1055 (64.3)               | 1155 (69.5)          | 38.34†              | <0.01       |
| Hyperlipidemia                              | 3545 (66.0)          | 1172 (70.3)              | 1120 (68.3)               | 1105 (66.5)          | 12.19†              | <0.01       |
| Previous stroke                             | 121 (2.3)            | 41 (2.5)                 | 49 (3.0)                  | 59 (3.6)             | 9.58†               | 0.02        |
| Peripheral vascular disease                 | 114 (2.1)            | 37 (2.2)                 | 35 (2.1)                  | 50 (3.0)             | 4.77†               | 0.19        |
| Family history of CAD                       | 1298 (24.2)          | 440 (26.4)               | 410 (25.0)                | 404 (24.3)           | 3.60†               | 0.31        |
| Current smoker                              | 3057 (56.9)          | 979 (58.7)               | 956 (58.3)                | 896 (53.9)           | 9.42†               | 0.02        |
| Previous MI                                 | 884 (16.4)           | 279 (16.7)               | 347 (21.1)                | 411 (24.7)           | 68.79†              | <0.001      |
| Previous PCI                                | 1203 (22.4)          | 399 (23.9)               | 439 (26.8)                | 475 (28.6)           | 32.89†              | <0.001      |
| Clinical presentation                       |                      |                          |                           |                      |                     |             |
| ACS                                         | 3334 (62.0)          | 983 (59.0)               | 941 (57.3)                | 979 (58.9)           | 12.68†              | <0.01       |
| Stable angina                               | 1620 (30.1)          | 546 (32.8)               | 559 (34.1)                | 534 (32.1)           |                     |             |
| Silent ischemia                             | 421 (7.8)            | 138 (8.3)                | 141 (8.6)                 | 148 (8.9)            |                     |             |
| Angiographic and procedural characteristics  |                      |                          |                           |                      |                     |             |
| CAD extension                               | 131 (2.4)            | 37 (2.2)                 | 50 (3.0)                  | 38 (2.3)             | 2.95†               | 0.40        |
| 3-vessel disease                            | 1228 (22.8)          | 815 (48.9)               | 989 (60.3)                | 1184 (71.3)          | 1659.30‡            | <0.01       |
| Type of stents                              |                      |                          |                           |                      |                     |             |
| BMS                                         | 27 (0.5)             | 10 (0.6)                 | 6 (0.4)                   | 14 (0.8)             | 3.92†               | 0.27        |
| DES                                         | 5198 (96.7)          | 1602 (96.1)              | 1537 (93.7)               | 1434 (86.3)          | 272.04†             | <0.01       |
| PTCA                                        | 104 (1.9)            | 33 (2.0)                 | 41 (2.5)                  | 52 (3.1)             | 9.37†               | 0.02        |
| IVUS use                                    | 302 (5.6)            | 89 (5.3)                 | 99 (6.0)                  | 90 (5.4)             | 0.90†               | 0.83        |
| IABP use                                    | 57 (1.1)             | 15 (0.9)                 | 17 (1.0)                  | 50 (3.0)             | 41.70†              | <0.01       |
| Procedural success                          | 5329 (99.1)          | 1645 (98.7)              | 1584 (96.5)               | 1500 (90.3)          | 385.39†             | <0.01       |
| Baseline SYNTAX score                       | 9.0 ± 6.5            | 11.3 ± 6.6               | 14.2 ± 6.3                | 20.8 ± 7.5           | 1381.2*             | <0.01       |

The data are shown as mean ± SD or n (%). *F value; †Chi-square value. BMI: Body mass index; eGFR: Estimated glomerular filtration rate; LVEF: Left ventricular ejection fraction; COPD: Chronic obstructive pulmonary disease; CAD: Coronary artery disease; MI: Myocardial infarction; PCI: Percutaneous coronary intervention; ACS: Acute coronary syndrome; BMS: Bare metal stent; DES: Drug-eluting stent; PTCA: Percutaneous transluminal coronary angioplasty; IVUS: Intravenous ultrasound; IABP: Intra-aortic balloon pump; CrSS: Clinical residual SYNTAX score; SD: Standard deviation; LM: Left main.
| Characteristics                              | SRI = 100 (n = 5375) | 100 > SRI ≥66.7 (n = 1610) | 66.7 > SRI ≥38.9 (n = 1702) | SRI <38.9 (n = 1657) | Statistical values | P for trend |
|--------------------------------------------|----------------------|-----------------------------|-----------------------------|----------------------|--------------------|-------------|
| **Age (years)**                            | 57 ± 10              | 59 ± 10                     | 59 ± 10                     | 60 ± 10              | 32.2*              | <0.01       |
| **Male**                                   | 4140 (77.0)          | 1237 (76.8)                 | 1305 (76.7)                 | 1286 (77.6)          | 0.47†              | 0.92        |
| **BMI (kg/m²)**                            | 25.9 ± 3.2           | 26.0 ± 3.2                  | 25.9 ± 3.1                  | 26.0 ± 3.1           | 8.76*              | 0.46        |
| eGFR <90 ml/min                            | 1871 (34.8)          | 642 (39.9)                  | 713 (41.9)                  | 719 (43.4)           | 57.14              | <0.01       |
| LVEF <40 ml/min                            | 76 (1.4)             | 45 (2.8)                    | 25 (1.5)                    | 35 (2.1)             | 6.45†              | 0.09        |
| **Clinical history**                       |                      |                             |                             |                      |                    |             |
| Diabetes mellitus                          | 1398 (26.0)          | 571 (35.5)                  | 578 (34.0)                  | 561 (33.9)           | 88.01†             | <0.01       |
| Hypertension                               | 3321 (61.8)          | 1097 (68.1)                 | 1125 (66.1)                 | 1098 (66.3)          | 30.22†             | <0.01       |
| Hyperlipidemia                             | 3545 (66.0)          | 1106 (68.7)                 | 1161 (68.2)                 | 1130 (68.2)          | 6.91†              | 0.07        |
| Previous stroke                            | 491 (9.1)            | 185 (11.5)                  | 224 (13.2)                  | 209 (12.6)           | 31.90              | <0.01       |
| Peripheral vascular disease                | 121 (2.3)            | 42 (2.6)                    | 54 (3.2)                    | 53 (3.2)             | 7.10*              | 0.07        |
| COPD                                       | 114 (2.1)            | 33 (2.0)                    | 42 (2.5)                    | 47 (2.8)             | 3.56†              | 0.31        |
| Family history of CAD                      | 1298 (24.2)          | 403 (25.0)                  | 419 (24.6)                  | 432 (26.1)           | 2.59*              | 0.46        |
| Current Smoker                             | 3057 (56.9)          | 882 (54.8)                  | 978 (57.5)                  | 971 (58.6)           | 5.11†              | 0.16        |
| Previous MI                                | 884 (16.4)           | 321 (19.9)                  | 355 (19.7)                  | 381 (23.0)           | 40.85†             | <0.01       |
| Previous PCI                               | 1203 (22.4)          | 358 (22.2)                  | 452 (26.6)                  | 503 (30.4)           | 52.19†             | <0.01       |
| **Clinical presentation**                  |                      |                             |                             |                      |                    |             |
| ACS                                        | 3334 (62.0)          | 940 (58.4)                  | 1002 (58.9)                 | 961 (58.0)           | 13.08†             | <0.01       |
| Stable angina                              | 1620 (30.1)          | 539 (33.5)                  | 562 (33.0)                  | 538 (32.5)           | 6.91†              | 0.07        |
| Silent ischemia                            | 421 (7.8)            | 131 (8.1)                   | 138 (8.1)                   | 158 (9.5)            | 3.56†              | 0.31        |
| **Angiographic and procedural characteristics** |                    |                             |                             |                      |                    |             |
| **CAD extension**                          |                      |                             |                             |                      |                    |             |
| LM disease                                 | 131 (2.4)            | 86 (5.3)                    | 28 (1.6)                    | 11 (0.7)             | 82.21†             | <0.01       |
| 3-vessel disease                           | 1228 (22.8)          | 890 (55.3)                  | 1037 (60.9)                 | 1061 (64.0)          | 1513.11†           | <0.01       |
| **Type of stents**                         |                      |                             |                             |                      |                    |             |
| BMS                                        | 27 (0.5)             | 5 (0.3)                     | 10 (0.6)                    | 15 (0.9)             | 0.12               |             |
| DES                                        | 5198 (96.7)          | 1558 (96.8)                 | 1626 (95.5)                 | 1389 (83.8)          | <0.01              |             |
| PTCA                                       | 104 (1.9)            | 20 (1.2)                    | 38 (2.2)                    | 68 (4.1)             | 5.77†              | 0.12        |
| IVUS use                                   | 302 (5.6)            | 146 (9.1)                   | 75 (4.4)                    | 57 (3.4)             | 430.08†            | <0.01       |
| IABP use                                   | 57 (1.1)             | 37 (2.3)                    | 17 (1.0)                    | 28 (1.7)             | 36.13†             | <0.01       |
| Procedural success                         | 5329 (99.1)          | 1583 (98.3)                 | 1674 (98.4)                 | 1472 (88.8)          | 55.78†             | <0.01       |
| Baseline SYNTAX score                      | 9.0 ± 6.5            | 16.5 ± 7.6                  | 13.7 ± 7.7                  | 16.1 ± 8.1           | 17.34†             | <0.01       |

The data are shown as mean ± SD or n (%). *F value; †Chi-square value. BMI: Body mass index; eGFR: Estimated glomerular filtration rate; LVEF: Left ventricular ejection fraction; COPD: Chronic obstructive pulmonary disease; CAD: Coronary artery disease; MI: Myocardial infarction; PCI: Percutaneous coronary intervention; ACS: Acute coronary syndrome; BMS: Bare metal stent; DES: Drug-eluting stent; PTCA: Percutaneous transluminal coronary angioplasty; IVUS: Intravenous ultrasound; IABP: Intra-aortic balloon pump; SRI: SYNTAX revascularization index; SD: Standard deviation; LM: Left main.